<DOC>
	<DOCNO>NCT02376816</DOCNO>
	<brief_summary>The proposed phase I clinical trial pilot study evaluate safety biological activity rAAVrh74.MCK.micro-Dystrophin vector administer intramuscular route . This study evaluate micro-Dystrophin vector potential dystrophin replacement mechanism Duchenne Muscular Dystrophy . Two cohort undergo gene transfer standard three-six dose escalation scheme establish maximum tolerate dose ( MTD ) use toxicity . A minimum three subject enrol cohort . The first cohort receive total dose 3E11 vg . The second cohort receive 1E12 vg total dose .</brief_summary>
	<brief_title>Clinical Intramuscular Gene Transfer Trial rAAVrh74.MCK.Micro-Dystrophin Patients With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>The primary objective study assessment safety intramuscular administration rAAVrh74.MCK.micro-Dystrophin Extensor Digitorum Brevis ( EDB ) muscle patient Duchenne Muscular Dystrophy ( DMD ) . Safety assess change hematology , serum chemistry , urinalysis , immunologic response rAAVrh74 micro-Dystrophin protein , report history observation symptom . Subjects evaluate baseline , injection visit ( day 0-2 ) , return follow visit day 7 , 14 , 30,60 , 90 , 180 end 1st 2nd year . On Day 180 , subject undergo muscle biopsy inject muscle one foot compare placebo-treatment opposite foot establish transgene expression potential toxicity gene transfer .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Age 7 older ; must wheelchairdependent Confirmed Dystrophin mutation base mutation compatibility microdys cDNA base previously publish method . Males ethnic group eligible . Ability cooperate muscle testing . Willingness sexually active subject reproductive capacity practice reliable method contraception ( If appropriate ) . Active viral infection base clinical observation . Symptoms sign cardiomyopathy , include : Dyspnea exertion , pedal edema , shortness breath upon lie flat , rales base lung Echocardiogram ejection fraction 40 % Serological evidence HIV infection , Hepatitis A , B C infection Diagnosis ( ongoing treatment ) autoimmune disease Concomitant illness requirement chronic drug treatment opinion PI create unnecessary risk gene transfer . Subjects AAVrh74 bind antibody titer â‰¥ 1:50 determined ELISA immunoassay . Abnormal laboratory value clinically significant range define protocol base upon normal value Nationwide Children 's Hospital Laboratory .</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DMD</keyword>
	<keyword>muscular dystrophy</keyword>
	<keyword>dystrophin</keyword>
</DOC>